Онкогематология (Nov 2022)

Treatment of invasive pulmonary aspergillosis according to recommendations of Infectious Diseases Society of Americaриведена в соответствии со стандартной системой, используемой в руководствах IDSA.

  • G. A. Klyaksova,
  • A. A Maschan,
  • A. V. Veselov

DOI
https://doi.org/10.17650/1818-8346-2008-0-1-2-47-57
Journal volume & issue
Vol. 0, no. 1-2
pp. 47 – 57

Abstract

Read online

Some recommendations of Infectious Diseases Society of America for diagnosis and treatment of invasive aspergillosis with lung involvement, which is the most frequent clinical manifestation of aspergillar infection.Full version of recommendations was published in one of the editions of journal “Clinical microbiology and antibacterial chemotherapy” (2008. Т. 10. №2). Fungi of Aspergillus kin is the main etiologic cause of life-threatening infections in immunocompromised patients, such as patients with prolonged neutropenia, advanced stages of HIV infection, hereditary immunodeficiency states and after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and/or lung transplantation. This version of recommendations for treatment of invasive aspergillosis from IDSA (Infectious Diseases Society of America) substituted the former recommendations published in 2000. The level of evidence of treatment data is given in according with standard scheme used in the IDSA guidance.

Keywords